Gene Therapy in CNS Disorder Market 2023 to 2033: Advanced R&D Process Strategies

Posted by Ganesh Shinde on March 23rd, 2023

The global gene therapy in CNS disorders market is predicted to generate a market value of US$ 8.2 billion in 2023 and a market value of US$ 113.04 billion by 2033, with a CAGR of 30% from 2023 to 2033. In the historical period 2018 to 2022, the market for gene therapy in CNS illnesses grew at a CAGR of 19%.

One of the key drivers of this growth is the increasing prevalence of CNS disorders, particularly neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. As the global population ages, the incidence of these disorders is expected to increase, creating a significant healthcare burden and driving demand for effective treatments.

In addition, the growing investment in gene therapy research and development is expected to accelerate the development of new treatments for CNS disorders. The FDA and other regulatory agencies have established expedited pathways for the review and approval of gene therapy treatments, allowing for faster development and commercialization of these treatments.

Key Takeaways from the Market Study 

• From 2018 to 2022, the Gene Therapy in CNS Disorder market grew at a CAGR of 19%.
• The global Gene Therapy in CNS Disorder market is expected to grow with a 30% CAGR during 2023 to 2033.
• As of 2033, the Gene Therapy in CNS Disorder Market is expected to reach US$ 113.04 Billion.
• According to the FMI analysis, hospitals account for the largest market share.
• North America is expected to possess 40% market share for the Gene Therapy in CNS Disorder market. 
• The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period. 

Market Competition

Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.

Browse More@ https://www.futuremarketinsights.com/reports/gene-therapy-in-cns-disorder-market

Key Segments Profiled in the Gene Therapy in CNS Disorder Industry Survey

Indication:

• Alzheimer's Disease
• Huntington's Disease
• Parkinson's Disease
• Batten Disease

Type:

• Ex Vivo
• In Vivo

End User:

• Hospitals
• Speciality Clinics